Budesonide and fluticasone propionate differentially affect the airway epithelial barrier

BACKGROUND: COPD patients have a higher risk of pneumonia when treated with fluticasone propionate (FP) than with placebo, and a lower risk with budesonide (BUD). We hypothesized that BUD and FP differentially affect the mucosal barrier in response to viral infection and/or cigarette smoke. METHODS:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Respir Res
Autors principals: Heijink, I. H., Jonker, M. R., de Vries, M., van Oosterhout, A. J. M., Telenga, E., ten Hacken, N. H. T., Postma, D. S., van den Berge, M.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704248/
https://ncbi.nlm.nih.gov/pubmed/26739349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-015-0318-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars